首页> 外文期刊>American journal of medical genetics, Part A >Clinical and Laboratory Outcomes After Umbilical Cord Blood Transplantation in a Patient with Mucolipidosis II Alpha/Beta
【24h】

Clinical and Laboratory Outcomes After Umbilical Cord Blood Transplantation in a Patient with Mucolipidosis II Alpha/Beta

机译:脐血移植II粘液脂蛋白II Alpha / Beta患者的脐带血移植后的临床和实验室结果

获取原文
获取原文并翻译 | 示例
           

摘要

Mucolipidosis (ML) II alpha/beta is an autosomal recessive disease caused by reduced enzyme activity of N-acetylglucosamine-1-phosphotransferase. Clinical symptoms of ML II are severe psychomotor delay and dysostosismultiplex; death usually occurs by 5-8 years of age from cardiopulmonary complications. Allogeneic hematopoietic stem cell transplantation (HSCT) has been attempted for ML; however, few reports have documented the detailed outcomes of HSCT for ML. A 26-month-old girl received a human leukocyte antigen 3/6-allele-matched transplant from cord blood. The preparative regimen consisted of fludarabine, cyclophosphamide, 6-Gy total body irradiation, and rabbit antithymocyte globulin. Although comparing before and after cord blood transplantation results, we observed that lysosomal enzyme activities in the plasma decreased by approximately 20-40%. Low serum levels of immunoglobulin A, G2, and G4 were also observed before HSCT; however, these values normalized after transplantation. Despite undergoing HSCT, she was treated twice for bacterial pneumonia with acute respiratory distress syndrome at ages 37 and 38 months. Although HSCT effects on the clinical manifestations were limited, laboratory data including plasma lysosomal enzyme activities and serum levels of immunoglobulin showed improvement. (C) 2016 Wiley Periodicals, Inc.
机译:血脂异常(ML)II alpha / beta是一种常染色体隐性遗传疾病,由N-乙酰氨基葡萄糖-1-磷酸转移酶的酶活性降低引起。 ML II的临床症状是严重的精神运动延迟和多发性口臭。死亡通常在5-8岁时因心肺并发症而发生。 ML已经尝试了异基因造血干细胞移植(HSCT)。但是,很少有报道记录HSCT对ML的详细结果。一名26个月大的女孩从脐带血中接受了人类白细胞抗原3 / 6-等位基因匹配的移植。制备方案由氟达拉滨,环磷酰胺,6-Gy全身照射和兔抗胸腺细胞球蛋白组成。尽管比较了脐带血移植前后的结果,但我们观察到血浆中的溶酶体酶活性下降了约20-40%。 HSCT前也观察到血清免疫球蛋白A,G2和G4的水平较低;但是,这些值在移植后已正常化。尽管接受了HSCT治疗,但她在37个月和38个月时接受过两次细菌性肺炎合并急性呼吸窘迫综合征的治疗。尽管HSCT对临床表现的影响有限,但实验室数据包括血浆溶酶体酶活性和血清免疫球蛋白水平显示有所改善。 (C)2016威利期刊公司

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号